Patents by Inventor Thomas P. Quinn
Thomas P. Quinn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11660354Abstract: Described herein are novel conjugates containing an inhibitor (e.g., a PSMA inhibitor, e.g., a gastrin-releasing peptide receptor inhibitor) and metal chelator that are covalently attached to a macromolecule (e.g., a nanoparticle, a polymer, a protein). Such conjugates exhibit distinct properties over the free, unbound inhibitor/chelator construct.Type: GrantFiled: November 29, 2017Date of Patent: May 30, 2023Assignees: Memorial Sloan Kettering Cancer Center, Cornell University, The Curators of the University of MissouriInventors: Michelle S. Bradbury, Thomas P. Quinn, Barney Yoo, Wolfgang Weber, Karim Touijer, Howard Scher, Kai Ma, Ulrich Wiesner
-
Publication number: 20230037294Abstract: Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.Type: ApplicationFiled: October 7, 2022Publication date: February 9, 2023Inventors: Michelle S. Bradbury, Thomas P. Quinn, Feng Chen, Barney Yoo, Jason Lewis, Ulrich Wiesner, Kai Ma
-
Publication number: 20220306690Abstract: Provide for herein are cyclic or linear peptides that bind HIV-1 capsid protein and inhibit HIV-1 capsid from assembling and/or disassembling. Further provided are methods of making said peptides and pharmaceutical compositions and methods for treating HIV infection.Type: ApplicationFiled: June 8, 2020Publication date: September 29, 2022Inventors: Ujjwal Neogi, Anders Sonnerborg, Kamlendra Singh, Thomas P. Quinn, Fabio Gallazzi
-
Publication number: 20200353096Abstract: Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.Type: ApplicationFiled: December 19, 2019Publication date: November 12, 2020Inventors: Michelle S. Bradbury, Thomas P. Quinn, Feng Chen, Barney Yoo, Jason Lewis, Ulrich Wiesner, Kai Ma
-
Patent number: 10548989Abstract: Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.Type: GrantFiled: April 7, 2016Date of Patent: February 4, 2020Assignees: Memorial Sloan Kettering Cancer Center, Cornell University, The Curators of the University of MissouriInventors: Michelle S. Bradbury, Thomas P. Quinn, Feng Chen, Barney Yoo, Jason Lewis, Ulrich Wiesner, Kai Ma
-
Publication number: 20190282712Abstract: Described herein are novel conjugates containing an inhibitor (e.g., a PSMA inhibitor, e.g., a gastrin-releasing peptide receptor inhibitor) and metal chelator that are covalently attached to a macromolecule (e.g., a nanoparticle, a polymer, a protein). Such conjugates exhibit distinct properties over the free, unbound inhibitor/chelator construct.Type: ApplicationFiled: November 29, 2017Publication date: September 19, 2019Inventors: Michelle S. Bradbury, Thomas P. Quinn, Barney Yoo, Wolfgang Weber, Karim Touijer, Howard Scher, Kai Ma, Ulrich Wiesner
-
Patent number: 10039847Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: GrantFiled: September 25, 2017Date of Patent: August 7, 2018Inventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson, Thomas P. Quinn
-
Publication number: 20180133342Abstract: Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.Type: ApplicationFiled: April 7, 2016Publication date: May 17, 2018Applicants: Memorial Sloan Kettering Cancer Center, The Curators of the University of Missouri, Cornell University, The Curators of the University of MissouriInventors: Barney Yoo, Thomas P. Quinn, Michelle S. Bradbury, Ulrich Wiesner, Jason Lewis, Kai Ma, Feng Chen
-
Publication number: 20180093000Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: ApplicationFiled: September 25, 2017Publication date: April 5, 2018Inventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson, Thomas P. Quinn
-
Publication number: 20150335768Abstract: The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity selected population, was chemically synthesized and characterized for its binding activities to the recombinant extracellular domain of ErbB-2. The synthetic peptide exhibits high specificity to ErbB-2 as well as to ErbB-1, another member of ErbB family. Thus, this peptide can be employed in cancer imaging or therapeutic agent targeting to malignant cells ErbB-2 receptor.Type: ApplicationFiled: June 2, 2015Publication date: November 26, 2015Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Thomas P. QUINN, Natalia G. KARASSEVA
-
Patent number: 9061054Abstract: The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity selected population, was chemically synthesized and characterized for its binding activities to the recombinant extracellular domain of ErbB-2. The synthetic peptide exhibits high specificity to ErbB-2 as well as to ErbB-1, another member of ErbB family. Thus, this peptide can be employed in cancer imaging or therapeutic agent targeting to malignant cells ErbB-2 receptor.Type: GrantFiled: September 8, 2009Date of Patent: June 23, 2015Assignee: The Curators of The University of MissouriInventors: Thomas P. Quinn, Natalia G. Karasseva
-
Publication number: 20100061930Abstract: The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity selected population, was chemically synthesized and characterized for its binding activities to the recombinant extracellular domain of ErbB-2. The synthetic peptide exhibits high specificity to ErbB-2 as well as to ErbB-1, another member of ErbB family. Thus, this peptide can be employed in cancer imaging or therapeutic agent targeting to malignant cells ErbB-2 receptor.Type: ApplicationFiled: September 8, 2009Publication date: March 11, 2010Inventors: Thomas P. Quinn, Natalia G. Karasseva
-
Patent number: 7585509Abstract: The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity selected population, was chemically synthesized and characterized for its binding activities to the recombinant extracellular domain of ErbB-2. The synthetic peptide exhibits high specificity to ErbB-2 as well as to ErbB-1, another member of ErbB family. Thus, this peptide can be employed in cancer imaging or therapeutic agent targeting to malignant cells ErbB-2 receptor.Type: GrantFiled: July 3, 2003Date of Patent: September 8, 2009Assignee: The Curators of The University of MissouriInventors: Thomas P. Quinn, Natalia G. Karasseva
-
Publication number: 20080293161Abstract: The present invention generally relates to detection of carbohydrate biomarkers in nipple aspirate fluid samples. One aspect of the invention is a method for assaying a nipple aspirate fluid for the presence of TF or Tn carbohydrate biomarker. The assay generally employs an immobilized capture agent specific for TF or Tn and can be further coupled to either direct or indirect detection of bound TF or Tn carbohydrate biomarker through the use of a labeled binding agent.Type: ApplicationFiled: August 6, 2008Publication date: November 27, 2008Applicant: The Curators of the University of MissouriInventors: Susan L. Deutscher, Thomas P. Quinn, Edward R. Sauter
-
Patent number: 6680045Abstract: A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.Type: GrantFiled: April 24, 2001Date of Patent: January 20, 2004Assignee: The Curators of the University of MissouriInventors: Silvia S. Jurisson, Thomas P. Quinn, Michael F. Giblin
-
Patent number: 6607709Abstract: A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.Type: GrantFiled: October 11, 2000Date of Patent: August 19, 2003Assignee: The Curators of the University of MissouriInventors: Silvia S. Jurisson, Thomas P. Quinn, Michael F. Giblin
-
Patent number: 6338834Abstract: A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.Type: GrantFiled: April 30, 1998Date of Patent: January 15, 2002Assignee: The Curators of the University of MissouriInventors: Silvia S. Jurisson, Thomas P. Quinn, Michael F. Giblin
-
Publication number: 20010038822Abstract: A compound for use as a diagnostic or therapeutic pharmaceutical and method of using the same where the compound consists essentially of an alpha-melanotropin stimulating hormone analog which has integrally located a radionuclide. The radionuclide is administered to the body in an amount sufficient to allow uptake and retention by the tumor cells.Type: ApplicationFiled: April 24, 2001Publication date: November 8, 2001Inventors: Silvia S. Jurisson, Thomas P. Quinn, Michael F. Giblin
-
Patent number: 6154680Abstract: Computer-based industrial control systems and methods employing object oriented hardware elements. An object oriented hardware element may comprise a processor core coupled one side to a universal real-world interface circuit, and on the other side to an open bus interface. In a preferred embodiment, the open bus interface provides downloading software programming objects to the microprocessor core. A computer-based control system in accordance with the present invention may comprise a personal computer or central processing unit coupled to a communications network, at least one zone interface module coupled to the communications network and to an open bus, at least one zone device module coupled to the open bus and, if required, one or more zone processor modules coupled to the open bus. Software object may be downloaded from the personal computer or central processing unit to the various modules to achieve modular, exception-based, distributively intelligent (MEDI) I/O control within the system.Type: GrantFiled: October 7, 1997Date of Patent: November 28, 2000Assignee: Zone Automation Inc.Inventors: H. Philip White, Thomas P. Quinn, James B. Quinn, John F. Stine
-
Patent number: 5231816Abstract: A method of packaging a beverage having gas in solution has an open topped container 1 in which is located a hollow insert 5 having a restricted aperture 12. The container is charged with the beverage such as beer 15 so that the aperture 12 is submerged in the beverage and the container is sealed to form a headspace 19 which is pressurized, preferably by dosing with liquid nitrogen. Following sealing the container is rapidly inverted to locate the aperture 12 in the headspace 19 so that gas pressures in the insert chamber 10 and the headspace 19 come into equilibrium. With the fluid contents in equilibrium, or substantially so, the package is reinverted so that gas under pressure in the insert chamber 10 communicates directly by way of the aperture 12 with beer in the chamber 10.Type: GrantFiled: June 17, 1992Date of Patent: August 3, 1993Assignee: Guinness Brewing Worldwide LimitedInventors: Francis J. Lynch, Michael W. Coleman, Thomas P. Quinn